Max Healthcare Institute Ltd.
NSE: MAXHEALTHMax Healthcare Institute Ltd.: A 30-second snapshot
Max Healthcare trades at 1,070, down 15.86% over the past year and 17.65% below its 52-week high, though up 4.46% over the past 3 months and holding above its 200-day average (1,053.87) while sitting just under its 50-day average (1,073.94). Trailing PE of 72.44x sits near the top of a 6-stock Pharma peer group (29.50x-85.47x) even as return on equity (14.33%) has not exceeded 15% in any tracked year. Mean analyst rating stands at 2.0 across 26 analysts (1-5 scale, lower = more constructive).
P/E
72.4
Forward P/E
44.1
ROE
+14.3%
Debt / Equity
32.37
Profit Margin
+17.2%
Div. Yield
+0.2%
5Y ROE > 15%
0/5
5Y FCF > 0
4/5
Quality
55/100
News
5 headlines · 0 positive · 1 negative
Max Healthcare Updates on NCLT Proceedings Involving Kalinga Hospital Subsidiary - TipRanks
TipRanks
Max Healthcare Schedules Q1 FY27 Earnings Call for Investors - TipRanks
TipRanks
Max Healthcare completes dissolution process for Nigerian subsidiary - TipRanks
TipRanks
Max Healthcare Publishes Transcript of 25th AGM Held Via Video Conference - TipRanks
TipRanks
HDFC Life Falls 1.8% Despite 12% Profit Rise in Q1 FY27 - Whalesbook
Whalesbook
Recent context
- ·2026-08-07: company update on NCLT proceedings involving the Kalinga Hospital subsidiary, tagged negative sentiment.
- ·2026-08-08: Q1 FY27 earnings call scheduled.
- ·2026-07-29 and 2026-08-05: dissolution of the Nigerian subsidiary completed and the 25th AGM transcript published, both tagged neutral.
Strengths
- +Free cash flow was positive in 4 of the tracked years.
- +Return on equity ranks 2nd of 6 tracked Pharma peers despite not exceeding 15% in any single tracked year.
- +Price is up 4.46% over the past 3 months and remains above its 200-day moving average (1,053.87).
- +Profit margin of 17.23% alongside 5-year revenue growth of 12.2%.
Weaknesses
- −Return on equity has not exceeded 15% in any tracked year; consistency score of 43/100 and a quality score of 37 that ranks 4th of 6 tracked Pharma peers.
- −Trailing PE of 72.44x ranks 5th (highest) of 6 tracked peers, while 5-year earnings growth (7.4%) has trailed 5-year revenue growth (12.2%).
- −A disclosure dated 2026-08-07 on NCLT proceedings involving the Kalinga Hospital subsidiary was the sole negative-sentiment headline in the tracked 5-item news sample.
- −Leverage has trended higher across the tracked persistence window even though free cash flow stayed positive in 4 of those years; the stock is down 15.86% over the trailing 12 months.
Open questions
- ?What specifically underlies the NCLT proceedings involving the Kalinga Hospital subsidiary, and what is the disclosed scope or timeline?
- ?Does the gap between trailing PE (72.44x) and forward PE (44.15x) reflect a realistic near-term earnings step-up, or does it rest on assumptions not yet visible in trailing numbers?
- ?Why has leverage trended higher across the tracked window even though free cash flow stayed positive in 4 of those years?
- ?What would need to change in return on equity, which has stayed below 15% in every tracked year, for the quality score to move up relative to the 6-stock Pharma peer set?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| MAXHEALTH | Max Healthcare Institute Ltd.You're viewing | 72.4 | +14.3% | 37 |
| Industry avg | across 5 peers | 51.0 | +15.2% | 38 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| DIVISLAB | Divi's Laboratories Ltd. | 85.5 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 29.5 | +8.8% | 4 |
Technical state
Current price
₹1,070.00
SMA 50
₹1,073.94
SMA 200
₹1,053.87
RSI (14)
43.4 (neutral)
From 52w high
-17.6%
1Y return
-15.9%
3M return
+4.5%
50-DMA
Below
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumReturn on equity of 14.33% has not exceeded 15% in any tracked year, alongside a consistency score of 43 out of 100; the quality score of 37 ranks 4th of 6 tracked Pharma peers.
- mediumTrailing PE of 72.44x sits near the top of the tracked Pharma peer range (29.50x-85.47x), ranking 5th of 6 on PE, while forward PE of 44.15x is well below the trailing figure; 5-year earnings growth (7.4%) has trailed 5-year revenue growth (12.2%) over the same window.
- mediumA headline dated 2026-08-07 discloses active NCLT proceedings involving the company's Kalinga Hospital subsidiary, tagged negative sentiment; this is the only substantive negative company-specific item in a 5-headline sample.
- lowThe news sample for the tracked window totals only 5 headlines, and one item ('HDFC Life Falls 1.8% Despite 12% Profit Rise in Q1 FY27') does not reference MAXHEALTH and appears to be off-target or misclassified coverage.
Cross-section contradictions
- Free cash flow was positive in 4 of the tracked years, yet leverage has trended higher over the same window; debt-to-equity of approximately 0.32x remains low in absolute terms, but cash generation has not corresponded with a decline in leverage.
- MAXHEALTH ranks 2nd of 6 tracked Pharma peers on return on equity (14.33%) but 5th of 6 on trailing PE (72.44x), placing valuation toward the high end of the peer range relative to its profitability rank.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 9 Aug 2026 · rotates through NIFTY 500 every ~5 days